Profitelligence Profitelligence · Filing Ledger Open AMGN research →

Form 8-K · Current Report · Filed 2026-04-22

Amgen Announces Retirement of Chief Technology Officer David M. Reese

Amgen Inc. announced on April 22, 2026, that David M. Reese, Executive Vice President and Chief Technology Officer, will retire effective June 30, 2026. His responsibilities will be redistributed to James E. Bradner, Murdo Gordon, and Peter H. Griffith. Dr. Reese, who joined Amgen in 2005, led approvals of numerous innovative medicines and advanced the company's adoption of technology and artificial intelligence.

Filer
Amgen Inc. AMGN · NASDAQ
Filed
Accession
0000318154-26-000048
CIK
0000318154
Signal
High impactHealthcare

Items reported

Item events

Reported Item

CTO Resignation Key Executive Departure

Market reaction

Close before filing

$344.86

Next session

+1.1%

Since filing

+11.7%

Latest close

$385.16

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from AMGN reporting the same item, with the next session's move:

Insider tape

Within 45 days of this filing, AMGN insiders reported 59 Form 4 transactions — net buying of $67.9M.

Full AMGN insider history →

About Amgen Inc.

Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.

Exchange NASDAQ Industry Drug Manufacturers - General Company website ↗

Never miss another AMGN filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts